{"id":"W4387809564","doi":"10.1016/j.annonc.2023.10.063","title":"LBA15 Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Osimertinib; Medicine; Oncology; Chemotherapy; Internal medicine; Randomized controlled trial; Chemotherapy regimen; Adenocarcinoma; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001387786,0.001805409,0.003351556,0.0004954987,0.0003019195,0.001178418,0.0009309027,0.001354258,0.00447785],"category_scores_gemma":[0.001070993,0.0006044112,0.002737757,0.0005249965,0.001034461,0.001093779,0.0004271625,0.003263707,0.0008481442],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009178017,"about_ca_system_score_gemma":0.001048893,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001470751,"about_ca_topic_score_gemma":0.003773649,"domain_scores_codex":[0.9995531,0.0002086844,0.00003005051,0.00009339276,0.00003368124,0.00008104823],"domain_scores_gemma":[0.9994959,0.0001324215,0.0001299118,0.00003260055,0.00002897085,0.0001802532],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9679538,0.003276414,0.0007108384,0.0009367093,0.002397864,0.00003090274,0.00004336675,0.0005530107,0.002060185,0.0001326881,0.0009062432,0.02099795],"study_design_scores_gemma":[0.9446456,0.04982588,0.001957238,0.00007788752,0.001550861,0.00003291756,0.00003068617,0.0005930973,0.0003995957,0.000196543,0.0006711594,0.00001851699],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.980996,0.01182862,0.0005007057,0.0008372637,0.0008353929,0.001581126,0.0008762268,0.0001538523,0.002390938],"genre_scores_gemma":[0.9864066,0.005365196,0.0009424702,0.001174434,0.0003924794,0.001604996,0.0009966561,0.0000332328,0.00308393],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00447785,"threshold_uncertainty_score":0.01497996,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03023174112253548,"score_gpt":0.4507468949399455,"score_spread":0.42051515381741,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}